Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-29

FDA Approved: TWIRLA — Supplemental Application (Agile Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TWIRLA (levonorgestrel/ethinyl estradiol) from Agile Therapeutics, Inc., indicating approval of changes under a …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TWIRLA (Levonorgestrel/ethinyl estradiol)

Snippet

SUPPL AP for TWIRLA (LEVONORGESTREL/ETHINYL ESTRADIOL)